The National Medical Products Administration conditionally approved the listing of Sefevolitinib tablets.

Recently, the National Medical Products Administration approved the conditional marketing of the innovative drug, Atezolizumab, developed by Bayer HealthCare Pharmaceuticals Inc., through the priority review process. This drug is indicated for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer in adult patients with HER2 activating mutations who have previously received at least one systemic therapy. The marketing of this drug provides a new treatment option for patients.